Quidel's RapidVue hCG lateral flow pregnancy immunoassay granted FDA 510(k) clearance
Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of Quidel's RapidVue® hCG test, a lateral flow pregnancy immunoassay for the qualitative detection of human Chorionic Gonadotropin (hCG).
Read more on News-Medical-Net
